Shanghai RAAS Blood Products (002252.SZ) has obtained a drug clinical trial approval letter.

Shanghai RAAS Blood Products (002252.SZ) announced that its wholly-owned subsidiary, Zhengzhou Lai Shi Blood Products Co., Ltd. ("Zhengzhou Lai Shi"), has received two acceptance letters from the National Medical Products Administration regarding the clinical trial application of "human fibrinogen". This product is derived from healthy human plasma, separated, purified, and processed through virus removal and inactivation, and lyophilized. It contains stabilizers such as glycine and lysine hydrochloride, without preservatives or antibiotics. Indications: congenital fibrinogen deficiency or absence (Acceptance No.: CXSL2400799, Notice No.: 2025LP00335); acquired fibrinogen deficiency: severe liver damage; cirrhosis; disseminated intravascular coagulation; postpartum hemorrhage and coagulation disorders caused by fibrinogen deficiency due to major surgery, trauma or internal bleeding (Acceptance No.: CXSL2400800, Notice No.: 2025LP00336).